NBIX (NASDAQ: NBIX) logs $1.51M 10b5-1 stock sale streak
Rhea-AI Filing Summary
Neurocrine Biosciences (NBIX) reports that an affiliate through Morgan Stanley Smith Barney LLC’s Executive Financial Services plans to sell 4,367 shares of common stock on 07/10/2026, in connection with an Exercise of Stock Options for cash. The planned sale reflects an indicated value of 788,461.85. In the prior three months, Ingrid Delaet completed multiple Rule 10b5-1 sales of NBIX common stock, including 8,433 shares on 07/09/2026 for 1,507,134.80 and additional sales on 07/08/2026, 07/07/2026, and 05/29/2026.
Positive
- None.
Negative
- None.
Insights
Planned NBIX insider sales continue under a Rule 10b5-1 trading plan.
The filing describes a plan to sell 4,367 shares of NBIX common stock tied to an Exercise of Stock Options, with an indicated value of 788,461.85. This is a registration for potential resale, not a new share issuance by the company.
It also lists recent Rule 10b5-1 transactions by Ingrid Delaet, including 8,433 shares on 07/09/2026 for 1,507,134.80, plus 2,737 shares on 07/08/2026, 3,401 shares on 07/07/2026, and 2,261 shares on 05/29/2026. Because these are pre-arranged plan sales, they are typically viewed as routine liquidity rather than discretionary trading.
Key Figures
Key Terms
Form 144 regulatory
Exercise of Stock Options financial
10b5-1 Sales regulatory
Executive Financial Services financial
AI-generated analysis. How Rhea-AI works. Not financial advice.